• EMBL Australia Newsletter - September 2022

    Newsletters / 8 September 2022

    News this quarter:

    • What exactly is EMBL Australia? A 60-second video to explain.
    • Biotech start-up receives funding for muscular dystrophies
    • Grants won to fight obesity and study cell size regulation
    • 2022 PhD Course inspires attendees
    • Talking mRNA with the PM
    • Max Cryle wins Tregear Award
    • Get to know… Ville-Petteri Mäkinen

    And more:

    • Job opportunities
    • Student opportunities
    • Upcoming events
    • Recent publications
    View Newsletter
  • Understanding how putting the hand brake on genes could halt cancer

    News / 2 August 2021

    Genes in the human genome are made of DNA. Upon gene expression, a segment of DNA is copied into another molecule called RNA. When gene regulation goes wrong, diseases like cancer can occur. Therefore, knowing how enzymes — highly efficient protein nanomachines — work to switch genes on and off enables the development of new drugs and diagnostics.

    Read More
  • EMBL Australia Newsletter – June 2021

    Newsletters / 28 June 2021

    News this quarter:

    • Lights out for Parkinson’s disease
    • Major Cancer Council grant for Dr Weatheritt
    • Discovery may help boost peptide design
    • Professor David Lynn talks everything COVID vaccines
    • 2021 EMBL Australia PhD Course applications
    • 2021 EMBL Australia Postgraduate Symposium registrations now open
    • 2020 Highlights report now available

    And more:

    • Job opportunities
    • Student opportunities
    • Upcoming events
    • Recent publications
    View Newsletter
  • Discovery may help boost peptide design

    News / 6 May 2021

    Research led by EMBL Australia group leader Max Cryle has revealed a key aspect of peptide machineries, advancing his work in countering the global threat of antimicrobial resistance and having broad implications for health and industry.

    Read More
  • Lights out for Parkinson's disease

    News / 15 April 2021

    Research led by EMBL Australia group leader Dr Harald Janovjak has revealed the potential of optogenetics - a relatively new and rapidly evolving technology - to treat Parkinson's disease.
    Read More
  • EMBL Australia Newsletter - March 2021

    Newsletters / 17 March 2021

    News this quarter:

    • A tribute to Scientia Professor Katharina Gaus FAHMS
    • Reversing severe muscle wasting in disease, ageing & trauma
    • Hint as to how SARS-CoV-2 might subvert immune defences
    • Enabling the early and accurate diagnosis of Parkinson’s disease
    • More than $4.8m awarded to EMBL Australia researchers in NHMRC Ideas Grants
    • This protein empowers cancer cells – targeting it could kickstart new therapies
    • Professor Ian Smith to chair the EMBL Australia Council
    • Innovative research takes us one step closer to developing an effective malaria vaccine
    • Did you know you can access EMBL’s cutting-edge scientific services?
    • Get to know: Dr Vaishnavi Ananthanarayanan

     

    And more:

    • Job opportunities
    • Upcoming events
    • Recent publications
    View Newsletter